表紙
市場調査レポート

アレナウイルス感染症ラッサ熱- パイプライン製品の分析

Arenavirus Infection Lassa Fever - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321909
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
アレナウイルス感染症ラッサ熱- パイプライン製品の分析 Arenavirus Infection Lassa Fever - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 42 Pages
概要

ラッサ熱は、急性の出血性疾患で、アレナウイルス科のウィルスによって引き起こされます。げっ歯類の排泄物によって汚染された食品や日用品に接触することにより、ヒトに感染します。症状は熱、頭痛、悪寒、背部痛、体重減少、首のむくみ、発疹、出血等です。

当レポートでは、アレナウイルス感染症ラッサ熱に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

アレナウイルス感染症ラッサ熱の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Profectus BioSciences, Inc.
  • SIGA Technologies, Inc

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤のプロファイル

  • EMER-IT
  • lassa fever vaccine
  • lassa fever vaccine 1
  • lassa fever vaccine 2
  • Monoclonal Antibodies for Viral Infections
  • Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus
  • ST-161
  • ST-193

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7135IDB

Summary

Global Markets Direct's, 'Arenavirus Infection Lassa Fever - Pipeline Review, H2 2015', provides an overview of the Arenavirus Infection Lassa Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arenavirus Infection Lassa Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arenavirus Infection Lassa Fever
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arenavirus Infection Lassa Fever and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arenavirus Infection Lassa Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arenavirus Infection Lassa Fever pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arenavirus Infection Lassa Fever
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arenavirus Infection Lassa Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Arenavirus Infection Lassa Fever Overview
  • Therapeutics Development
    • Pipeline Products for Arenavirus Infection Lassa Fever - Overview
    • Pipeline Products for Arenavirus Infection Lassa Fever - Comparative Analysis
  • Arenavirus Infection Lassa Fever - Therapeutics under Development by Companies
  • Arenavirus Infection Lassa Fever - Therapeutics under Investigation by Universities/Institutes
  • Arenavirus Infection Lassa Fever - Pipeline Products Glance
    • Early Stage Products
  • Arenavirus Infection Lassa Fever - Products under Development by Companies
  • Arenavirus Infection Lassa Fever - Products under Investigation by Universities/Institutes
  • Arenavirus Infection Lassa Fever - Companies Involved in Therapeutics Development
    • Etubics Corporation
    • Profectus BioSciences, Inc.
    • SIGA Technologies, Inc.
  • Arenavirus Infection Lassa Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FBH-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lassa fever vaccine 1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lassa fever vaccine 2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arenavirus Infection Lassa Fever - Recent Pipeline Updates
  • Arenavirus Infection Lassa Fever - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arenavirus Infection Lassa Fever, H2 2015
  • Number of Products under Development for Arenavirus Infection Lassa Fever - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Arenavirus Infection Lassa Fever - Pipeline by Etubics Corporation, H2 2015
  • Arenavirus Infection Lassa Fever - Pipeline by Profectus BioSciences, Inc., H2 2015
  • Arenavirus Infection Lassa Fever - Pipeline by SIGA Technologies, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Arenavirus Infection Lassa Fever Therapeutics - Recent Pipeline Updates, H2 2015
  • Arenavirus Infection Lassa Fever - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Arenavirus Infection Lassa Fever, H2 2015
  • Number of Products under Development for Arenavirus Infection Lassa Fever - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top